ArticleBritish journal of cancer1997
p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?
Article in British journal of cancer, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 76 citations in OpenAlex.
- Prognostic Value of Retinoblastoma in Small Intestinal Adenocarcinoma: A Multicenter Retrospective Study.Journal of Korean medical science · 2024Article
- Correlation between expression levels of lncRNA FER1L4 and RB1 in patients with colorectal cancer.Molecular biology reports · 2021Article
- Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Tailoring to RB: tumour suppressor status and therapeutic response.Nature reviews. Cancer · 2008Review
- p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.International journal of colorectal disease · 2007Article
- Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma.World journal of gastroenterology · 2006Article
- Article
- p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.British journal of cancer · 2005Article
- Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.International journal of colorectal disease · 2004Article
- Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.International journal of colorectal disease · 2004Review
- [Clinical, pathological and molecular prognostic factors in colorectal carcinomas].Der Pathologe · 2003Review
- Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.Journal of clinical pathology · 2002Article
- Tumour markers of prognosis in colorectal cancer.British journal of cancer · 1999Article
- Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.British journal of cancer · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of the p53 and Rb1 proteins was examined in an unselected consecutive series of 250 primary operable colorectal carcinomas with a mean follow-up of 4.3 years (range 43-77 months). The overall cancer-specific mortality was 34.8%, with 87 cancer deaths and 35 deaths as the result of other causes. Expression of p53 protein was identified in 152 of 250 (60.8%) cases, with expression of Rb1 protein in 207 of 250 (82.8%) cases. There was no association of p53 or Rb protein expression with patient age, sex, tumour site, tumour size, tumour type, tumour grade, peritumoral fibrosis, tumour lymphocytic infiltrate, nature of the tumour margin, extramural vascular invasion, number of lymph nodes or high apical lymph node involved or local peritoneal infiltration by tumour, Dukes' stage or Jass group. There was no difference in overall survival or recurrence-free survival for those cases that showed p53 expression or Rb1 protein expression compared with those cases showing absence of p53 or Rb1 protein expression, although patients with tumours showing aberrant (reduced) Rb1 protein expression demonstrated shorter recurrence-free survival and overall survival. The effect of 'aberrant' Rb1 protein expression and shorter recurrence-free and overall survival did not, however, achieve independent statistical significance. The results from this study would suggest that expression of p53 and Rb1 proteins does not appear be useful in determining the prognosis of operable colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.